392 related articles for article (PubMed ID: 17015892)
1. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.
Deandreis D; Rubino C; Tala H; Leboulleux S; Terroir M; Baudin E; Larson S; Fagin JA; Schlumberger M; Tuttle RM
J Nucl Med; 2017 May; 58(5):717-722. PubMed ID: 27738010
[TBL] [Abstract][Full Text] [Related]
5. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
6. Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma.
Van Nostrand D; Atkins F; Moreau S; Aiken M; Kulkarni K; Wu JS; Burman KD; Wartofsky L
Thyroid; 2009 Oct; 19(10):1093-8. PubMed ID: 19732012
[TBL] [Abstract][Full Text] [Related]
7. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
8. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
[TBL] [Abstract][Full Text] [Related]
9. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer.
Kulkarni K; Van Nostrand D; Atkins F; Aiken M; Burman K; Wartofsky L
Thyroid; 2006 Oct; 16(10):1019-23. PubMed ID: 17042688
[TBL] [Abstract][Full Text] [Related]
10. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
[TBL] [Abstract][Full Text] [Related]
11. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
12. [Changes in the blood picture after radioiodine therapy of thyroid cancer].
Grünwald F; Schomburg A; Menzel C; Steinecker S; Späth G; Bockisch A; Fimmers R; Hotze AL; Biersack HJ
Med Klin (Munich); 1994 Oct; 89(10):522-8. PubMed ID: 7808352
[TBL] [Abstract][Full Text] [Related]
13. [Experience with a high-dose therapy concept in metastatic differentiated thyroid cancer].
Grünwald F; Ruhlmann J; Ammari B; Knopp R; Hotze A; Biersack HJ
Nuklearmedizin; 1988 Dec; 27(6):266-71. PubMed ID: 3217257
[TBL] [Abstract][Full Text] [Related]
14. 131I ablation treatment in young females after the Chernobyl accident.
Travis CC; Stabin MG
J Nucl Med; 2006 Oct; 47(10):1723-7. PubMed ID: 17015910
[TBL] [Abstract][Full Text] [Related]
15. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
16. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule.
Sgouros G; Song H; Ladenson PW; Wahl RL
J Nucl Med; 2006 Dec; 47(12):1977-84. PubMed ID: 17138740
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 contamination from thyroid cancer patients.
Ibis E; Wilson CR; Collier BD; Akansel G; Isitman AT; Yoss RG
J Nucl Med; 1992 Dec; 33(12):2110-5. PubMed ID: 1460501
[TBL] [Abstract][Full Text] [Related]
18. [Dosimetry of the hematopoietic system in radioiodine therapy of thyroid cancer].
Günter HH; Junker D; Schober O; Hundeshagen H
Strahlenther Onkol; 1987 Mar; 163(3):185-91. PubMed ID: 3563879
[TBL] [Abstract][Full Text] [Related]
19. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer.
Glanzmann C
Strahlenther Onkol; 1992 Jun; 168(6):337-43. PubMed ID: 1621212
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
Brierley J; Tsang R; Panzarella T; Bana N
Clin Endocrinol (Oxf); 2005 Oct; 63(4):418-27. PubMed ID: 16181234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
